Koers Tauriga Sciences, Inc. Other OTC
Aandelen
TAUG
US87669X2053
Farmaceutische producten
Omzet 2020 | 0,23 0,22 | Omzet 2021 | 0,29 0,26 | Marktkapitalisatie | 29,3 mln. 27,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2020 | -3 mln. -2,79 mln. | Nettowinst (verlies) 2021 | -3 mln. -2,79 mln. | EV/omzet 2020 | 15.901.203 x |
Nettoschuld 2020 | 373K 347K | Nettoliquiditeiten 2021 | 1,04 mln. 965K | EV/omzet 2021 | 99.058.952 x |
K/w-verhouding 2020 |
-0,87
x | K/w-verhouding 2021 |
-6,09
x | Werknemers | - |
Dividendrendement 2020 * |
-
| Dividendrendement 2021 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Seth M. Shaw
CEO | Chief Executive Officer | 45 | 22-08-12 |
Kevin P. Lacey
DFI | Director of Finance/CFO | 55 | 05-07-17 |
Keith A. Aqua
CTO | Chief Tech/Sci/R&D Officer | - | 15-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James V. Rosati
BRD | Director/Board Member | 74 | 08-03-21 |
Seth M. Shaw
CEO | Chief Executive Officer | 45 | 22-08-12 |
Director/Board Member | 46 | 08-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |